Tarsa Therapeutics Raises $24 Million
Tarsa Therapeutics Inc. has raised $24 million in Series A funding. MVM Life Science Partners led the round, and was joined by Quaker BioVentures and Novo AS. In related news, Unigene Laboratories Inc. (OTCBB: UGNE) has licensed its Phase III oral calcitonin program to Tarsa, in exchange for a 25% ownership position.
21 October 2009•5 mins read
